Global research trends on Chinese patent drugs inducing programmed cell death in cancer: a bibliometric analysis (1998–2024)
Abstract Background Chinese patent drugs, standardized formulations rooted in traditional Chinese medicine, have gained attention for their potential to induce programmed cell death (PCD) in cancer cells. Emerging evidence suggests that these formulations may affect multiple PCD pathways, including...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-06-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02913-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849686104926584832 |
|---|---|
| author | Min Song Chunyan Teng Xiaodong Zheng Shizhen Tan Yipeng Guo |
| author_facet | Min Song Chunyan Teng Xiaodong Zheng Shizhen Tan Yipeng Guo |
| author_sort | Min Song |
| collection | DOAJ |
| description | Abstract Background Chinese patent drugs, standardized formulations rooted in traditional Chinese medicine, have gained attention for their potential to induce programmed cell death (PCD) in cancer cells. Emerging evidence suggests that these formulations may affect multiple PCD pathways, including apoptosis, autophagy, ferroptosis, pyroptosis, and necroptosis, thus offering a multifaceted approach to tumor suppression. Objectives This study aimed to map the global research landscape on Chinese patent drugs in cancer-related PCD, examining publication trends, principal contributors, and thematic evolutions. The analysis also sought to provide insights that could guide future investigations and clinical applications. Methods Bibliometric data were extracted from the Web of Science Core Collection (1998–2023), focusing on articles investigating Chinese patent drugs and PCD in oncological contexts. R-bibliometrix was used for descriptive statistics and trend analyses, while VOSviewer generated network visualizations of co‐occurring keywords, collaboration patterns, and co‐citation clusters. Results Overall publication output increased markedly, with China leading in both volume and impact. Collaboration networks revealed extensive international partnerships, underscoring global interest in standardized herbal formulations. Keyword mapping highlighted a shift from early apoptosis-centric studies to more diverse regulated cell‐death pathways, indicating greater mechanistic depth and exploration of synergistic effects with conventional therapies. Conclusion Chinese patent drugs are increasingly recognized as promising agents for modulating PCD in cancer cells. Ongoing work focuses on standardized manufacturing, robust clinical validation, and mechanistic elucidation. These trends position Chinese patent drugs at a pivotal juncture for advancing integrative oncology and enhancing patient outcomes. |
| format | Article |
| id | doaj-art-b585116eb5d848c7b78bf0a163bd0efc |
| institution | DOAJ |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-b585116eb5d848c7b78bf0a163bd0efc2025-08-20T03:22:50ZengSpringerDiscover Oncology2730-60112025-06-0116112010.1007/s12672-025-02913-5Global research trends on Chinese patent drugs inducing programmed cell death in cancer: a bibliometric analysis (1998–2024)Min Song0Chunyan Teng1Xiaodong Zheng2Shizhen Tan3Yipeng Guo4Department of Pharmacy, Chongqing Beibei Hospital of Traditional Chinese Medicine, Chongqing Hospital of The First Affiliated Hospital of Guangzhou University of Chinese MedicineDepartment of Spleen-Stomach Diseases, Chongqing Beibei Hospital of Traditional Chinese Medicine, Chongqing Hospital of The First Affiliated Hospital of Guangzhou University of Chinese MedicineIntroduction Of PKU HealthCare Corp., Ltd.Department of Management Information, Chongqing Beibei Hospital of Traditional Chinese Medicine, Chongqing Hospital of The First Affiliated Hospital of Guangzhou University of Chinese MedicineDepartment of Pharmacy, Hubei Provincial Hospital of Integrated Traditional Chinese & Western MedicineAbstract Background Chinese patent drugs, standardized formulations rooted in traditional Chinese medicine, have gained attention for their potential to induce programmed cell death (PCD) in cancer cells. Emerging evidence suggests that these formulations may affect multiple PCD pathways, including apoptosis, autophagy, ferroptosis, pyroptosis, and necroptosis, thus offering a multifaceted approach to tumor suppression. Objectives This study aimed to map the global research landscape on Chinese patent drugs in cancer-related PCD, examining publication trends, principal contributors, and thematic evolutions. The analysis also sought to provide insights that could guide future investigations and clinical applications. Methods Bibliometric data were extracted from the Web of Science Core Collection (1998–2023), focusing on articles investigating Chinese patent drugs and PCD in oncological contexts. R-bibliometrix was used for descriptive statistics and trend analyses, while VOSviewer generated network visualizations of co‐occurring keywords, collaboration patterns, and co‐citation clusters. Results Overall publication output increased markedly, with China leading in both volume and impact. Collaboration networks revealed extensive international partnerships, underscoring global interest in standardized herbal formulations. Keyword mapping highlighted a shift from early apoptosis-centric studies to more diverse regulated cell‐death pathways, indicating greater mechanistic depth and exploration of synergistic effects with conventional therapies. Conclusion Chinese patent drugs are increasingly recognized as promising agents for modulating PCD in cancer cells. Ongoing work focuses on standardized manufacturing, robust clinical validation, and mechanistic elucidation. These trends position Chinese patent drugs at a pivotal juncture for advancing integrative oncology and enhancing patient outcomes.https://doi.org/10.1007/s12672-025-02913-5Programmed cell deathApoptosisCancerMulti-target therapyChinese patent drugIntegrative oncology |
| spellingShingle | Min Song Chunyan Teng Xiaodong Zheng Shizhen Tan Yipeng Guo Global research trends on Chinese patent drugs inducing programmed cell death in cancer: a bibliometric analysis (1998–2024) Discover Oncology Programmed cell death Apoptosis Cancer Multi-target therapy Chinese patent drug Integrative oncology |
| title | Global research trends on Chinese patent drugs inducing programmed cell death in cancer: a bibliometric analysis (1998–2024) |
| title_full | Global research trends on Chinese patent drugs inducing programmed cell death in cancer: a bibliometric analysis (1998–2024) |
| title_fullStr | Global research trends on Chinese patent drugs inducing programmed cell death in cancer: a bibliometric analysis (1998–2024) |
| title_full_unstemmed | Global research trends on Chinese patent drugs inducing programmed cell death in cancer: a bibliometric analysis (1998–2024) |
| title_short | Global research trends on Chinese patent drugs inducing programmed cell death in cancer: a bibliometric analysis (1998–2024) |
| title_sort | global research trends on chinese patent drugs inducing programmed cell death in cancer a bibliometric analysis 1998 2024 |
| topic | Programmed cell death Apoptosis Cancer Multi-target therapy Chinese patent drug Integrative oncology |
| url | https://doi.org/10.1007/s12672-025-02913-5 |
| work_keys_str_mv | AT minsong globalresearchtrendsonchinesepatentdrugsinducingprogrammedcelldeathincancerabibliometricanalysis19982024 AT chunyanteng globalresearchtrendsonchinesepatentdrugsinducingprogrammedcelldeathincancerabibliometricanalysis19982024 AT xiaodongzheng globalresearchtrendsonchinesepatentdrugsinducingprogrammedcelldeathincancerabibliometricanalysis19982024 AT shizhentan globalresearchtrendsonchinesepatentdrugsinducingprogrammedcelldeathincancerabibliometricanalysis19982024 AT yipengguo globalresearchtrendsonchinesepatentdrugsinducingprogrammedcelldeathincancerabibliometricanalysis19982024 |